A novel method providing a more accurate LDL-C assessment leading to a more robust basis for personalized clinical decision-making
Find out more about why the Friedewald formula could lead to possible undertreatment of high-risk patients, and how to use the new method for a more accurate LDL-C assessment.
Clinical Testing for Titin and Ryanodine Receptor Autoantibodies in Myasthenia Gravis Patients
Find out more here
A new study supports assessment of family history and genetic predisposition in addition to established cardiometabolic risk factors.
Learn more here
Geographic Disparities in Access to Syringe Services Programs Among Young People with Hepatitis C Virus Infection in the US
Learn more here
Click here if you want to learn more about LRP4 Autoimmune Reactivity in a Diverse Double-Seronegative MG Patient Population
Improving the Positive Predictive Value of Noninvasive Prenatal Screening (NIPS)
Read more here how this technologically advanced cfDNA-based prenatal screening assay demonstrates excellent discrimination between affected and unaffected pregnancies for trisomies 21, 18, and 13.
This educational webinar is presented in Spanish. Quest Diagnostics Arturo Anguiano, MD, delivers this educational webinar for the benefit of those in Spanish speaking markets.... Read more ▸
Assessment of LDL-C in the Modern Era: Using a More Accurate LDL-C Estimate to Inform Personalized Clinical Decision-Making
Dr Martin explains the limitations of Friedewald-estimated LDL cholesterol; identifies patients in whom it is less accurate and how to recognize a more accurate, validated... Read more ▸
Dr. Opesanmi discusses testing recommendations beyond drug monitoring for the injection drug user. Read more ▸